26 Mar 2026 08:00 CET

Issuer

AKER BIOMARINE ASA

26 March 2026: Aker BioMarine ASA today publishes its Annual Report for 2025,
which includes the annual accounts, the sustainability statement and the
auditor's report for 2025.

The report is attached and is also available at www.akerbiomarine.com.

Aker BioMarine ASA has also published its annual financial statements in
European
Single Electronic Format (ESEF), available as an attachment to this release.

For further information, please contact
Christopher Robin Vinter, SVP Finance
Mobile: +47 911 60 820
Email: Christopher.vinter@akerbiomarine.com

This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act.

About Aker BioMarine
Aker BioMarine is a leading human health and nutrition innovator that develops
krill-derived products for consumer health and nutrition. Krill is a natural,
powerful, and health-promoting source of nutrients from the pristine waters of
Antarctica, and Aker BioMarine has a unique position in its industry. The
ingredient portfolio consists of Superba Krill Oil, Lysoveta, Revervia, and PL+,
as well as the consumer brand, Kori Krill. The innovative approach also extends
into the spin-offs AION (reduce and recycle plastic waste across industries) and
Understory (a protein brand). Aker BioMarine is listed on the Oslo Stock
Exchange (AKBM). More information is available at www.akerbiomarine.com.


669359_AKBM Annual Report 2025.pdf
669359_AkerBioMarineASA-2025-12-31.zip

Source

Aker BioMarine ASA

Provider

Oslo Børs Newspoint

Company Name

AKER BIOMARINE ASA, Aker Biomarine ASA 24/27 FRN C

ISIN

NO0010886625, NO0013326025

Symbol

AKBM

Market

Euronext Oslo Børs